Renalytix AI PLC ADR (RNLX): Price and Financial Metrics


Renalytix AI PLC ADR (RNLX): $2.25

-0.07 (-3.02%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

RNLX POWR Grades

  • RNLX scores best on the Sentiment dimension, with a Sentiment rank ahead of 90.5% of US stocks.
  • RNLX's strongest trending metric is Stability; it's been moving up over the last 177 days.
  • RNLX's current lowest rank is in the Quality metric (where it is better than 6.34% of US stocks).

RNLX Stock Summary

  • RNLX's price/sales ratio is 22.42; that's higher than the P/S ratio of 94.76% of US stocks.
  • As for revenue growth, note that RNLX's revenue has grown 75.22% over the past 12 months; that beats the revenue growth of 90.28% of US companies in our set.
  • In terms of volatility of its share price, RNLX is more volatile than 86.95% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to RENALYTIX PLC, a group of peers worth examining would be STRM, VORB, ICAD, LVOX, and ISSC.
  • To check out RENALYTIX PLC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001811115.

RNLX Valuation Summary

  • In comparison to the median Healthcare stock, RNLX's EV/EBIT ratio is 118.18% lower, now standing at -1.2.
  • RNLX's price/sales ratio has moved NA NA over the prior 33 months.

Below are key valuation metrics over time for RNLX.

Stock Date P/S P/B P/E EV/EBIT
RNLX 2023-03-24 22.4 4.1 -1.6 -1.2
RNLX 2023-03-23 21.6 4.0 -1.6 -1.2
RNLX 2023-03-22 21.0 3.9 -1.5 -1.1
RNLX 2023-03-21 21.4 3.9 -1.6 -1.2
RNLX 2023-03-20 22.7 4.2 -1.7 -1.2
RNLX 2023-03-17 24.3 4.5 -1.8 -1.4

RNLX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RNLX has a Quality Grade of F, ranking ahead of 2.15% of graded US stocks.
  • RNLX's asset turnover comes in at 0.017 -- ranking 78th of 81 Healthcare stocks.
  • 500 - Internal server error

The table below shows RNLX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.017 0.425 -8.200
2021-03-31 0.014 0.582 -0.987
2020-06-30 0.000 NA 4.057

RNLX Stock Price Chart Interactive Chart >

Price chart for RNLX

RNLX Price/Volume Stats

Current price $2.25 52-week high $8.50
Prev. close $2.32 52-week low $1.05
Day low $2.18 Volume 20,600
Day high $2.37 Avg. volume 51,295
50-day MA $2.86 Dividend yield N/A
200-day MA $2.28 Market Cap 105.50M

Renalytix AI PLC ADR (RNLX) Company Bio


Renalytix AI Plc manufactures medical devices and equipment. It offers artificial intelligence for kidney disease. The company was founded on March 15,2018 and is headquartered in Penarth, the United Kingdom.


RNLX Latest News Stream


Event/Time News Detail
Loading, please wait...

RNLX Latest Social Stream


Loading social stream, please wait...

View Full RNLX Social Stream

Latest RNLX News From Around the Web

Below are the latest news stories about RENALYTIX PLC that investors may wish to consider to help them evaluate RNLX as an investment opportunity.

Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

LONDON and SALT LAKE CITY, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will be participating in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 14-16, 2023 in Snowbird, Utah. Due to the format of this event there are no formal company presentations. Management will be participating in one-on-one meetings with investors during the event and meetings can be requested through

Yahoo | February 9, 2023

Renalytix announces a c.$20.3 million private placement

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR A SOLICITATION TO BUY SECURITIES IN ANY JURISDICTION, INCLUDING THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA. NEITHER THIS ANNOUNCEMENT NOR ANYTHI

Yahoo | February 8, 2023

Renalytix and Partners Awarded $10 Million Horizon Europe Grant to Advance Personalized Medicine in Treating CKD Throughout Europe and the United States

Award for consortium of industry, academic and clinical research leaders to develop personalized drug response tests in chronic kidney diseaseLONDON and SALT LAKE CITY, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces the launch of PRIME-CKD*, a consortium of industry, academic and clinical research leaders, that aims to validate and implement in clinical practice, novel biomarker-based tests that predict response to existing drugs used by patients with chroni

Yahoo | January 26, 2023

Renalytix Completes Agreement with Veterans Administration to Integrate KidneyIntelX Testing across all Electronic Health Record systems

Significant milestone will make KidneyIntelX accessible to 960,000 veterans with chronic kidney diseaseLONDON and SALT LAKE CITY, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the execution of a Co-operative Research and Development Agreement (CRADA) with the U.S. Veterans Health Administration Innovation Ecosystem (VHA IE) to install the KidneyIntelX solution inside the VA Health System’s Cloud Infrastructure and interface it with the VA Electronic H

Yahoo | January 9, 2023

Renalytix Plc (NASDAQ:RNLX) Q1 2023 Earnings Call Transcript

Renalytix Plc (NASDAQ:RNLX) Q1 2023 Earnings Call Transcript November 30, 2022 Operator: Good morning and welcome to the Renalytix Conference Call to review First Quarter Fiscal 2023 Financial Results. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of today’s call. As a reminder, […]

Yahoo | December 7, 2022

Read More 'RNLX' Stories Here

RNLX Price Returns

1-mo -34.59%
3-mo 20.32%
6-mo 75.78%
1-year -67.49%
3-year N/A
5-year N/A
YTD 20.32%
2022 -88.24%
2021 -0.62%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6892 seconds.